ThursdayMar 28, 2024 10:05 am

Indiana Governor Enacts Bill Funding Psilocybin Research for First Responders, Veterans

Governor Eric Holcomb of Indiana recently signed a measure that includes provisions to fund clinical trials on psilocybin’s therapeutic benefits. The measure, which primarily focuses on healthcare issues, was recently amended to include language on psychedelics. The reform provisions that legislators included to the broader measure were obtained from a standalone bill from Senator Ed Charbonneau, which cleared the Senate in February. In a press release, Charbonneau stated that the bill’s intention was to provide funds to help research institutions in the state in conducting research on the possible use of psilocybin in the treatment of mental-health conditions, with a…

Continue Reading

TuesdayMar 26, 2024 10:00 am

University of Calgary Researchers Begin Testing Psilocybin as AUD Treatment

University of Calgary scientists want to conduct a trial on the use of psilocybin as a treatment for alcohol use disorder (AUD). The trial will be carried out at the Hotchkiss Brain Institute and will include 128 individuals with alcohol use disorder. Each of the participants will undergo sessions prior to and after treatment; they will each also be assigned to trained therapists to take them through talk-therapy. In a news release, the trial’s principal investigator, Dr. Leah Mayo, revealed that team members would start the study with psychotherapy then administer psilocybin and observe whether this improved the therapy’s effectiveness.…

Continue Reading

ThursdayMar 21, 2024 10:00 am

Study Suggests Psilocybin Mushrooms Trigger Enhanced Benefits on Brain Compared to Synthetic Versions

New research suggests that hallucinogenic mushrooms that contain psilocybin may be useful in the treatment of conditions such as anxiety, post-traumatic stress disorder and obsessive-compulsive disorders. Professor Bernard Lerer, the author of the study, stated that researchers were interested in psychedelics’ potential in managing treatment-resistant psychiatric disorders, including post-traumatic stress disorder, depression and even schizophrenia. Lerer, a psychiatry professor and the director of Hebrew University’s Hadassah BrainLabs Center for Psychedelic Research, explained that many reports had proposed that using extracts from mushrooms that contain psilocybin could have effects that were quantitatively and qualitatively different from chemical psilocybin, which is what…

Continue Reading

TuesdayMar 19, 2024 11:00 am

Study Shows Psilocybin Reduces Brain’s Reaction to Angry Faces

New research has discovered that psilocybin decreases the amygdala region’s response to seeing images of angry faces. The amygdala is responsible for processing emotions, particularly those linked to anxiety and fear. This region in the brain also links emotions to other things such as senses, memories and learning. This region’s activity affects social interactions as well as behaviors, including avoidance and aggression. Psilocybin is a compound that naturally occurs in some mushroom species known as magic mushrooms. The compound’s psychoactive properties can produce altered states of consciousness, which may include changes in an individual’s mood, perception and thought patterns. For…

Continue Reading

ThursdayMar 14, 2024 11:00 am

How Psychedelics Could Enable Soldiers Beat Trauma

Data from Veterans Affairs estimates that more than 120,000 veterans in the United States have died by suicide. Many more in America and other parts of the globe struggle with post-traumatic stress disorder as conflicts rear their heads globally. In Ukraine, the ministry of health estimates that close to four million individuals are living with post-traumatic stress disorder. To help manage this, many have turned to psychedelics, and for good reason. Last month, the country’s special parliamentary commission voted to set up a working group that would investigate the effectiveness of MDMA-assisted therapy on post-traumatic stress disorder. In a statement,…

Continue Reading

TuesdayMar 12, 2024 11:00 am

2024 Could See Significant Investments in Studying Solid Tumors, Psychedelics

Experts predict that one of the key focuses for investors this year will be neuroscience and cancer-focused companies, with psychedelics being a priority within the neuroscience space. The specialists project that 2024 may be another year of significant investment in studying solid tumors and psychedelic drugs after 2023 proved to be a major year for investment in psychedelics and cancer. In addition, these researched informed BioSpace that there would be increased interest in obesity and autoimmune disorders among biopharma investors. Psychedelics have attracted plenty of attention from the mainstream and scientific communities over the past several years, thanks to their…

Continue Reading

ThursdayMar 07, 2024 10:30 am

Okanagan Researchers Explore Whether Psychedelics Could Help Combat Alcoholism

Research has shown that psychedelics may be useful in the treatment of a range of mental-health conditions, including anxiety, depression and post-traumatic stress disorder. Now, Okanagan researchers are looking into whether psychedelics can help manage alcoholism. Okanagan Clinical Trials is among other sites in Finland and Canada taking part in this research. The researchers’ objective is to evaluate the effectiveness of psilocybin in treating alcohol use disorder. Psilocybin is the active ingredient found in hallucinogenic mushrooms. To participate in the trial, all volunteers go through screening after which they participate in  10 therapy sessions, with two of sessions including the…

Continue Reading

TuesdayMar 05, 2024 9:30 am

Harvard, Berkeley Unveil Far-Reaching Psychedelics Initiative

Harvard University and the University of California, Berkeley have announced a collaborative venture. Titled “Psychedelics in Society and Culture,” the collaboration aims to understand the social history and societal implications of psychedelics. In a notable departure from the nascent psychedelic industry’s focus on clinical outcomes, the collaborative initiative will focus on societal sciences, humanities and arts. Psychedelic-focused initiatives mostly focus on how psychedelic use affects the human body and typically study the clinical outcomes of using psychedelics such as psilocybin (magic mushrooms), LSD and MDMA against a myriad of mental disorders. A growing body of scientific literature has found that…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050